Animal Testing: Rationale for conducting studies, CPCSEA Guidelines
The use of animals in research is currently an essential component of the drug discovery process.
Animals help us advance our scientific understanding, serve as models to study disease, help us develop and test potential new medicines and therapies.
Animal testing has benefited researchers in understanding how to treat and prevent various conditions such as high blood pressure, diabetes, tuberculosis, polio, muscular dystrophy, and Parkinson's disease.
Education:
Undergraduate teaching to demonstrate effects of various drugs although this has been phased out in most institutes.
Postgraduate teaching to demonstrate the effects of various drugs, to determine the nature of an unknown drug for bioassay, screening methods and to learn skills e.g. administering drugs.
Research:
A larger number and a greater variety of animals are used in pure research than in applied research. This usually involves studies on embryogenesis, developmental biology, behaviour and breeding in Fruit flies, nematodes, mice and rats.
INTRODUCTION
The motto of Prevention of Cruelty to Animals (PCA) Act 1960 as amended in 1982 is to prevent infliction of unnecessary pain or suffering on animals.
The Central Government has constituted a Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), which is duty bound to take all such measures as may be necessary to ensure that animals are not subjected to unnecessary pain or suffering before, during or after the performance of experiments on them.
The goal of these guidelines is to promote the human care of animal used in biomedical and behavioural research and testing.
To avoid/minimize pain and suffering inflicted on experimental animals
Inspection of animal house facilities
It provides guidelines for -
Proper care, housing, breeding, maintenance, handling and use of experimental animals.
Source of experimental animals
Acceptable experimental procedures for anaesthesia and euthanasia.
Registration of establishments conducting animal experimentation or breeding of animals for this purpose.
Selection and assignment of nominees for the Institutional Animal Ethics Committees (IAEC) of the registered establishments.
Approval of Animal House Facilities on the basis of reports of inspections conducted by CPCSEA.
Permission for conducting experiments involving use of animals.
Recommendation for import of animals for use in experiments.
Action against establishments in case of established violation of any legal norm/stipulation.
Conduct of Training Programmes for the Nominees of CPCSEA.
Conduct/Support of Conference/Workshop on Animal Ethics.
To assure quality maintenance and safety of animals used in laboratory studies while conducting biomedical and behavioural research and testing of products.
Quarantine
2. Personal hygiene
3. Environment
4. Physical facility
5. Animal husbandry
6. Animal disposal
7. Documentation
This presentation is aimed at providing information on automation in the GLP practices in the pharmaceutical industry.
-Standard Operating Procedures.
-Documentation in GALP.
-Logs and Related Forms.
Clinical Research Regulation in European Union ShantanuThakre3
- On 16 April 2014, the European Commission adopted the new Clinical Trial Regulation (EU No 536/2014), repealing Directive 2001/20/EC.
- Although the Clinical Trial Regulation was adopted and entered into force in 2014, the timing of its application depends on confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit.
- The Regulation becomes applicable six months after the European Commission publishes notice of this confirmation.
This presentation is aimed at providing information on automation in the GLP practices in the pharmaceutical industry.
-Standard Operating Procedures.
-Documentation in GALP.
-Logs and Related Forms.
Clinical Research Regulation in European Union ShantanuThakre3
- On 16 April 2014, the European Commission adopted the new Clinical Trial Regulation (EU No 536/2014), repealing Directive 2001/20/EC.
- Although the Clinical Trial Regulation was adopted and entered into force in 2014, the timing of its application depends on confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit.
- The Regulation becomes applicable six months after the European Commission publishes notice of this confirmation.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
This presentation contain detailed information about the "Regulation Governing Clinical Trials In India,USA and Europe".And about the clinical trails and medical devices regulations in India.
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxFaizanShaikh204666
the presentation give idea about what is medical devices?
definition's given by cdsco and usfda
what is clinical investigation in evaluation in medical devices?
Requirements And Guidelines For Permission To Import / or Manufacture of New Drugs For Sale or To Undertake Clinical Trials
Schedule Y was introduced under the Drugs and Cosmetics Act 1940, to
introduce requirements for countries to get permission for:
Importing
Manufacturing new drugs
Conducting Clinical Trials.
Application for permission
Clinical Trial
Studies in specific population
Post marketing surveillance
Special studies: BA/BE studies
overview of Japan pharmaceutical regulatory authority - PMDANandhanan
PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.
Acceptance of foreign clinical trials.pptxdipakkendre2
FDA guidence for industry acceptance of foreign clinical trials. -
Clinical trials conducted under IND
Clinical trials not conducted under IND
Good clinical practices
Acceptance of foreign clinical studies
Waivers
Choice of control group in clinical trialsNagendra SR
To describe the general principles involved in choosing a control group for clinical trials intended to demonstrate the efficacy of a treatment and to discuss related trial design and conduct issues.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
This presentation contain detailed information about the "Regulation Governing Clinical Trials In India,USA and Europe".And about the clinical trails and medical devices regulations in India.
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxFaizanShaikh204666
the presentation give idea about what is medical devices?
definition's given by cdsco and usfda
what is clinical investigation in evaluation in medical devices?
Requirements And Guidelines For Permission To Import / or Manufacture of New Drugs For Sale or To Undertake Clinical Trials
Schedule Y was introduced under the Drugs and Cosmetics Act 1940, to
introduce requirements for countries to get permission for:
Importing
Manufacturing new drugs
Conducting Clinical Trials.
Application for permission
Clinical Trial
Studies in specific population
Post marketing surveillance
Special studies: BA/BE studies
overview of Japan pharmaceutical regulatory authority - PMDANandhanan
PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.
Acceptance of foreign clinical trials.pptxdipakkendre2
FDA guidence for industry acceptance of foreign clinical trials. -
Clinical trials conducted under IND
Clinical trials not conducted under IND
Good clinical practices
Acceptance of foreign clinical studies
Waivers
Choice of control group in clinical trialsNagendra SR
To describe the general principles involved in choosing a control group for clinical trials intended to demonstrate the efficacy of a treatment and to discuss related trial design and conduct issues.
Slide contains aspects of animal use in pharmacology laboratory.
Along with CPCSEA Guidelines (now CCSEA).
Laboratory animals experiment benefits as well as limitations.
Different animals used in laboratory.
• The Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) is a statutory Committee of Department of Animal Husbandry and Dairying (DAHD), Ministry of Fisheries, Animal Husbandry and Dairying (MoFAH&D) constituted under the Prevention of Cruelty to Animals (PCA) Act, 1960.
• CPCSEA is duty bound to take all such measures as may be necessary to ensure that animals are not subjected to unnecessary pain or suffering before, during or after performance of experiments on them.
INTRODUCTION
• For this purpose, the Committee formulated the Breeding of and Experiments on Animals (Control & Supervision) Rules, 1998 (amended in 2001 & 2006) to regulate the experimentation on animals.
• Under the provisions of the above rules, establishments who are engaged in Bio-medical research, breeding and trading of laboratory animals are required to get themselves registered with CPCSEA.
• There are 19 members in the present CPCSEA wherein Dr. O. P. Chaudhary, Joint Secretary (Animal Welfare) is the Chairman of CPCSEA and Dr. S. K. Dutta, Joint Commissioner (Animal Welfare) is the Member Secretary of CPCSEA.
Need of cpcsea
FUNCTIONS
Institutional Animals Ethics Committee (IAEC)
(a) Every experiment shall be performed by or under the supervision of a person duly qualified.
(b) That experiments are performed with due care and humanity and as far as possible experiments involving operations are performed under the influence of some anaesthetic of sufficient power to prevent the animals from feeling pain;
(c) That animals who, in the course of experiments under the influence of anaesthetics, are so injured that their recovery would involve serious suffering, are ordinarily medically allowed to death while still under influence of anaesthetic;
(d) That experiments on animals are avoided wherever it is possible to do so.
(e) That experiments on larger animals are avoided when it is possible to achieve the same results by experiments on small laboratory animals like guinea-pigs, rabbits, mice, rats etc;
(f) That, as far as possible, experiments are not performed merely for the purpose of acquiring manual skill;
(g) That animals intended for the performance of experiments are properly looked after before, during and after experiments;
(h) That suitable records are maintained with respect to experiments performed on animals
Members of iaec
• A. IAEC members from the establishment (05 members):
• i. One biological scientist
• ii. Two scientists from different biological disciplines
• iii. One veterinarian involved in the care of animal
• iv. One scientist in charge of animal facility of the establishment concerned
• B. Nominees from the CPCSEA:
• i. Main Nominee (01)
• ii. Link Nominee *
• iii. Scientist from outside the Institute (01)
• iv. Socially Aware Nominee (01)
Institutional Biosafety Committee (IBSC)
• Institutional Biosafety Committee (IBSC) is to be constituted in all centers engaged in genetic engineering researc
Ethical issues related to animal biotechnologyKAUSHAL SAHU
Introduction
Why are genetically modified animals produced?
Examples of transgenic animals
Why are animals used instead of genetically modified microbes or plants?
Ethical issues
Religious concerns
Responsibility of Scientists
Need for Guidelines
Conclusion
References
Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...Prachi Pandey
CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine,
surveillance, diagnosis, treatment and control of disease, personal
hygiene, location of animal facilities to laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and
training, transport of lab animals.
Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...RAHUL PAL
CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine,
surveillance, diagnosis, treatment and control of disease, personal
hygiene, location of animal facilities to laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and
training, transport of lab animals.
Biosimilars
A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). (A medicine whose active substance is made by a living organism.)
Biologicals
Biological medicines contain active substances from a biological source, such as living cells or organisms and are often produced by cutting-edge technology.
Biological medicinal product
Biological Medicinal Products, also known as biologics or biologicals, are medicinal products that are manufactured using biotechnology processes and derived from living organisms or their products. They can include vaccines, blood products, gene therapies, monoclonal antibodies, recombinant proteins, and other complex biological substances.
Biological Investigational Medicinal Product
Refer to biological products that are being investigated in clinical trials or research studies to evaluate their safety, efficacy, or pharmacokinetic properties. These products have not yet received marketing authorization and are still in the experimental phase.
In the European Union, A biological substance is referred as the active ingredient in biological products.
A "biological substance" is defined as "a substance that is produced by or extracted from a biological source
That requires a combination of physico-chemical-biological testing, along with the production process and its control, for its characterization and the determination of its quality.“
Examples: Immunologic medicines
Medicines derived from human blood and plasma
Medicines developed by means of recombinant DNA technology
Hybridoma and mAb methods
Advanced therapy medicinal products
The requirements of the EU centralized procedure.
The approval standards for biotechnology products are the same as for chemically synthesized medicines.
Both types of products must be safe and effective and have appropriate quality.
MAA for a biotechnology product must meet the standard dossier submission requirements
MAA must generally comply with the CTD format, including with respect to
Module I (administrative information, including labelling)
Module 2 (various summaries)
Module 3 (chemical, pharmaceutical, and biological information)
Module 4 (nonclinical reports)
Module 5 (clinical study reports)
The EU has approved the highest number of biosimilars worldwide, and consequently has the most extensive experience of their use and safety.
EMA has issued scientific guidelines to help developers conform to the strict regulatory requirements for approving biosimilars.
The guidelines have evolved to keep pace with rapid advances in biotechnology and analytical sciences, and they take on board increasing experience of clinical use.
All medicines produced using biotechnology and those for specific indications must be approved in the EU through EMA
Some biosimilars may be approved at national level, such as some low-molecular weight heparins derived from porcine intestinal mucosa.
Introduction
Definition
Classification
Regulatory registration procedure
Quality system requirements
Clinical evaluation
Investigation of medical devices
Summary
Medical devices are regulated by the National Medical Product Administration (NMPA), formerly the China Food and Drug Administration (CFDA)
Manufacturers must register their devices with the NMPA before selling or distributing in China.
The NMPA reviews all device applications and has strict requirements for submission documentation, testing, and clinical data.
Any instrument, apparatus, appliance, material, or other article whether used alone or in combination, including the software necessary for its proper application.
Diagnosis, prevention, monitoring, treatment or alleviation of disease
Diagnosis, monitoring, treatment, alleviation of compensation for an injury or handicap conditions
Investigation, replacement or modification for anatomy or a physiological process
Control of conception
The Chinese authorities (CFDA/NMPA) have their own quality management system requirements.
However, these “GMP requirements” are very similar to ISO 13485.
Therefore, manufacturers usually submit the ISO 13485 certificate.
However, the audit will review this certificate against the Chinese GMP requirements.
These audits are regularly carried out during the approval procedure and/or after a recall.
NMPA issued and implemented the "Guideline on Inspection of Quality Management System for Medical Device Registration" on October 10, 2022.
Product Life-cycle Process
The guideline specifies the basic requirements for registration inspection, self-inspection, commissioned inspection, and extended inspection, etc. Applicant needs to:
Ensure the design, development, production, and other process data to be true, accurate, complete, and traceable, and consistent with the registration application materials.
Carry out the registration QMS inspection in reference to the registration application materials, and focus on the design, development, procurement, production management, and quality control of the product.
For lower-risk medical devices (Class I and Class II), clinical evaluation may not always be required. However, higher-risk devices (Class III and implantable devices) generally require clinical evaluation.
The evaluation involves reviewing existing clinical data, scientific literature, and relevant clinical research to assess the safety and performance of the device.
All clinical trials for medical devices must follow China Good Clinical Practices
Clinical investigations are required if no equivalent devices can be found and safety and efficacy cannot be proven with other clinical and non-clinical data.
For certain medical devices, the NMPA may require clinical investigations, especially for novel devices or those with significant risk.
Clinical investigations involve conducting studies on human subjects to generate clinical data on the safety and effectiveness of the device.
DIETARY SUPPLEMENT
The purpose of dietary supplements, is to enhance or supplement the diet. Even though a product is marketed as a dietary supplement, it is still considered a medicine to the extent that it is meant to treat, diagnose, cure, or prevent diseases.
Tablets, capsules, soft gels, powders, bars, gummies, and liquid supplements are just a few of the many different forms that supplements can take.
It is a product that is intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid.
A dietary substance use by human to supplement the diet by increasing the total daily intake, or a concentrate, metabolite, constituent, extract, or combinations of these ingredients.
FDA Role
Companies can often introduce a dietary supplement to the market without notifying FDA.
FDA’s role in regulating dietary supplements primarily begins after products enter the marketplace.
If a product is found to be unsafe or not otherwise in compliance with the law, FDA can work with the company to bring the product into compliance or possibly remove it from the market.
FDA regulates both finished dietary supplement products and dietary ingredients.
FDA regulates dietary supplements under a different set of regulations than those covering "conventional" foods (edible fruits and vegetables) and drug products.
Role of DSHEA
Manufacturers and distributors of dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded.
That means that these firms are responsible for evaluating the safety and labelling of their products before marketing to ensure that they meet all the requirements of the Federal Food, Drug, and Cosmetic Act (FFDCA) as amended by DSHEA and FDA regulations.
FDA has the authority to take action against any adulterated or misbranded dietary supplement product after it reaches the market
The Dietary Supplement Health and Education Act of 1994 was enacted to prohibit
Dietary supplement manufacturers and distributors from making false claims (such as "natural" and "therapeutic," on supplement labels)
The law also prohibits the manufacture and sale of adulterated dietary supplements.
Aim of these act:
To make dietary supplements safer by forbidding manufacturers and distributors from producing and selling mislabelled or adulterated products.
Act requires that the manufacturer of the dietary supplement ensures their product meets DSHEA and FDA regulations.
Table of Contents
Short Title Reference Table Of Contents
Findings
Definitions
Safety of Dietary Supplements and Burden of Proof on FDA
Dietary Supplement Claims
Statements of Nutritional Support
Dietary supplement ingredient labeling and nutrition information labeling
New dietary ingredients
Good manufacturing practices
Conforming amendments
Withdrawal of the regulations and notice
Commission on dietary supplement labels
GCC countries, Drug registration regulations of Saudi Arabia, Medicinal Product Registration process (SA), Drug Registration Requirement (SA), Post Registration Requirements in (SA), Drug registration regulations UAE Medicinal Product Registration process (UAE), Drug Registration Requirement (UAE).
Since 2003, The Saudi Food and Drug Authority (SFDA) is the competent authority for registrations, maintenance, quality, pharmacovigilance and import of medicinal products.
SFDA is responsible for handling and licensing the manufacture, import, export, distribution, promotion, and advertising of medicinal products.
The SFDA is also responsible for assessing the safety, efficacy, and quality of medicinal products, issuing marketing authorizations, and monitoring the quality & safety of the marketed medicinal products.
SFDA prefers the drug dossier submission in electronic format (eCTD).
It is an independent authority from the Ministry of Health.
Market Authorization
The process of submitting a new Marketing Authorization Application (MAA) consists of the following phases:
Phase 1
Step 1: Online Registration on the Drug Establishments National Registry (DENR)
The applicant register online on the DENR to get a username and password, which enables the applicant to log in and avail all the electronic services of the drug sector.
Step 2: Marketing Authorization Application (MAA) Submission:
The applicant shall apply through the Saudi Drug Registration (SDR) system to fill out the application form and pay the fees.
Upload the eCTD file to the system through the SDR system portal.
A soft copy of the eCTD should be submitted labelled as per the SFDA guideline, along with the hard copies of the original documents.
Phase 2
Step 1: Validation
The product file will be validated on technical and business bases to ensure that the applicant fulfils the requirement.
Step 2 - Assessment, Testing and Inspection
The relevant departments will evaluate the MAA to assess quality, safety, and efficacy, along with the onsite GMP inspection and sample analysis by the SFDA central laboratories.
Step 3 - Pricing
The Pricing Department will review the product’s price according to the “SFDA's pricing rules.”
Step 4 - Product Licensing
The Registration Committee will review the registration request for approval.
Verification and Abridged Procedure
Verification Process
This process will be applicable if the product has been approved and marketed by both the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA).
For all pharmaceutical items, even those that are not intended to be used as medicines, such as nutritional supplements and cosmetics, to be registered with the Ministry of Health & Prevention (MOHAP) in the United Arab Emirates.
The UAE government takes all necessary measures to ensure that safety standards and procedures are followed in cases of import, export, trade, and sale of products, which are consumed or used by the people.
Patents are a type of techno-legal document that describes novel, unique, and industrially applicable inventions. A request for the issuance of a patent for an invention created and detailed in the patent specification is known as a patent application.
a) Novelty: Before submitting the patent application in India, the subject matter specified in the specification was not published in India or anywhere else.
b) Inventive Step: A person who is experienced in the art would not recognize the invention in light of the earlier publication, knowledge, or document.
c) Industrial Applicability: In order to be produced or used in the industry, an invention must have some sort of utility.
DOCUMENTS REQUIRED FOR PATENT REGISTRATION:
1. (Form 1) Application form for the grant of patent in India.
2. (Form 2) If a provisional specification is submitted, it must be followed within a year by a complete specification. Provisional or complete specification of patent in duplicate.
3. (Form 3) Information and undertaking listing each foreign patent application's number, filing date, and current status in duplicate.
4. Priority document (if the priority date is claimed) in convention application, when directed by the Controller
5. (Form 5) When a complete specification follows a provisional specification, or in the event of a convention or PCT national phase application, an inventor declares their invention
ADVANTAGES OF REGISTERING A PATENT
1. A patent serves as a means of supporting innovations and inventions. The invention or concept belongs to the applicant after they receive the patent.
2. A business must register for a patent because a patent prevents competitors from stealing, selling, or importing the intellectual property without authorization.
3. In support of the current legislation, the patent holder can thereby defend his patent rights.
a) Like other types of property, patents can be bought, sold, or licensed.
b) Ownership of the patent may also be transferred by the inventor.
c) A patented product enhances brand recognition and can allow the company to charge more.
d) With exclusive patent rights, the inventor has long-term control over how the innovation is used.
e) Under the International Patent Protection Scheme, the government would cover up to Rs. 15 lakhs (or 50% of the total cost) of an MSME's international patent filing.
TRADEMARK: 1. A trademark is a symbol that can be used to separate the products or services of one company from those of other companies. Intellectual property rights provide protection for trademarks.
2. A trademark registration grants the owner of the trademark the sole right to use it. This suggests that the trademark may be used solely by its owner or may be licensed to a third party for use in exchange for payment.
COPYRIGHT: 1. The legal term "copyright" (sometimes known as "author's right") is used to refer to the ownership rights that authors and other artists have over their creative works.
DOCUMENT
A DOCUMENT is a piece of written, printed, or electronic matter that provides information or evidence or that serves as an official record.
WHY DOCUMENTATION
Documents and products are produced in pharmaceuticals but regulatory bodies are interested to see documents first.
Due to the importance given to documentation in pharma "good documentation practices" is required.
Good documentation is a systematic procedure of preparation, checking, verifying, issuing, storing and reviewing of any documents.
Clearly written documents prevent errors of various activities in Pharma.
PURPOSE OF DOCUMENTATION:
Defines specifications and procedures for all materials and methods of manufacture and control.
Ensures that all personnel knows what to do and when to do it.
Ensure that authorized persons have all information necessary for release of product.
Ensures documented evidence, traceability, provide records and audit trail for investigation.
Ensures availability of data for validation, review and statistical analysis.
Drug substance :
Drug substance is an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.
Drug product :
Drug product is a finished dosage form, e.g., tablet, capsule, or solution, that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients.
Exploratory Product Development Brief
Many companies today utilize some form of a traditional phased-and-gated product development process, which originated more than 50 years ago. It hasn’t changed substantially since then.
A phased-and-gated system creates multiple batches that slows down the overall speed of a product development project.
When companies try to maintain a traditional phased- and-gated process in a changing environment, the product development team is unable to manage to the scope, timeline and budget approved at the outset.
The result usually includes changing product requirements, unexpected problems, rework, schedule delays, breaking the budget and commercial failure.
GOAL
Develop Exploratory PD® (ExPD), which help companies achieve growth and improve product development success through an adaptive system.
The primary goal of ExPD is to reduce uncertainty and risk by reducing the unknown.
When organizations adapt quickly to the changing environment (market, technology, regulations, globalization, etc.), they reduce uncertainty and risk leading to product success.
APPROACH
The product development team needs an approach that allows them to adapt to change in customer needs, markets, competition, technology and more.
ExPD proposes a new approach to developing products, using a two-pronged solution:
1) Treating product development from a comprehensive systems perspective
This presentation contain introduction to Good Distribution Practices Guideline. and Legal GDP requirements put worldwide.
Good distribution practice (GDP) describes the minimum standards that a wholesale distributor must meet to ensure that the quality and integrity of medicines is maintained throughout the supply chain
Each participant in the distribution chain must agree by the relevant requirements in order to retain the original quality of pharmaceutical products.
Each activity in the distribution of pharmaceutical products shall be carried out according to the principles of Good Distribution Practices (GDP) as applicable.
The risks involved are likely to be of a nature comparable to those that are present in the industrial environment, such as mix-ups, adulteration, contamination, cross-contamination, and spurious.
The guideline addresses
Personnel
Quality System
Premises Warehousing and Storage
Documentation
Traceability
Complaints and Returns
Transportation
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Animal Testing: Rationale for conducting studies, CPCSEA Guidelines
1. Animal Testing: Rationale for
conducting studies, CPCSEA
Guidelines
Presented by:
Vanshika Gupta
1st sem M.Pharm (RA)
MRA104T
Parul Institute Of Pharmacy
Parul University 1
2. Content
Animal testing
Advantages & Disadvantages of Animal Testing
Animal Welfare Initiatives In Selected Countries In
Asia
Rationale for conducting studies
CPCSEA Guideline
Maintenance of laboratory animals as per CPCSEA
guidelines
2
3. Animal Testing
Animal testing is use to help us understand diseases, for
assessing the safety of a wide range of substances, including
medications, vaccines, food additives, household items,
workplace chemicals, cosmetics, water and air pollutants.
About 10 million animals around the world are being tested
every year.
84% are Rodents
12% are Fish, Amphibians, & Reptiles
2.1% are Large Mammals
1.4% are Small Mammals
0.3% are Dogs & Cats and 0.1% are Primates
3
4. Cont...
Animal experimentation is conducted all over the world.
Universities and Medical Schools
Pharmaceutical & Biotechnology companies
Military Defence Establishments (nuclear trials, military
sonars)
The reason for animal experimentation is to tests substances
and procedures to see if they are harmful or it would be safe
for human use.
Many of these experiments cause pain to the animals
involved or reduce their quality of life in other ways.
4
5. Advantages of Animal Testing
o Can help to save many lives by curing the diseases.
o Understanding certain bacteria and viruses.
o Useful to treat future pandemics.
o Invention of new medicines, New vaccines.
o Can increase our overall life expectancy.
o Safety improvements for customers.
5
6. Disadvantages of Animal
Experimentation
o Animals have to scarify for our research.
o May be considered to be cruel.
o Animal testing may not be acceptable regarding religious
aspects.
o Animal testing can be expensive.
o May not be suitable to determine long-term effects.
6
7. Animal Welfare Initiatives In
Selected Countries In Asia
Country Animal Welfare Initiatives
India -Prevention of Cruelty to Animals Act, 1960
-Institutional Animal Ethic Committee (IAEC)
-Animal Welfare Board of India (AWBI)
-Committee for the Purpose of Supervision and
Control of Experiments on Animals (CPCSEA)
China -The Animal Husbandry Law of People Republic
of China (2006)
-Farm Animal welfare requirement for pigs
Indonesia -Animal welfare legislation, 1967.
7
8. Cont...
Philippines -Animal Welfare Act, 1998
South Korea -Korean Animal Welfare Advisory
Committee
Malaysia -The Malaysian Animal Welfare Act, 2016
-Prevention of Cruelty to Animals, 1910.
Singapore -National Advisory Committee for
Laboratory Animal Research (NACLAR)
Thailand -National Research Council of Thailand
-Ethical Principles and Guidelines for the
Use of Animals for Scientific Purposes 1999
8
9. Rationale for conducting studies
The use of animals in research is currently an essential
component of the drug discovery process.
Animals help us advance our scientific understanding, serve
as models to study disease, help us develop and test
potential new medicines and therapies.
Animal testing has benefited researchers in understanding
how to treat and prevent various conditions such as high
blood pressure, diabetes, tuberculosis, polio, muscular
dystrophy, and Parkinson's disease.
9
10. Cont...
Humans are 98% genetically similar to mice.
Animals are susceptible to many of the same health
problems as humans – cancer, diabetes, heart disease, etc.
Research on animal models has advanced the understanding
and development of clinical and medical sciences.
For example, guinea pigs and frogs were heroes in the
process of inventing asthma inhalers.
Meningitis C cases are now rare, going down to 700 cases
per year through the last decade.
10
11. Cont...
Education:
Undergraduate teaching to demonstrate effects of various
drugs although this has been phased out in most institutes.
Postgraduate teaching to demonstrate the effects of various
drugs, to determine the nature of an unknown drug for
bioassay, screening methods and to learn skills e.g.
administering drugs.
11
12. Cont...
Research:
A larger number and a greater variety of animals are used in
pure research than in applied research. This usually involves
studies on embryogenesis, developmental biology,
behaviour and breeding in Fruit flies, nematodes, mice and
rats.
i. Cosmetic testing
ii. Toxicology testing
12
13. CPCSEA
INTRODUCTION
The motto of Prevention of Cruelty to Animals (PCA) Act
1960 as amended in 1982 is to prevent infliction of
unnecessary pain or suffering on animals.
The Central Government has constituted a Committee for
the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), which is duty bound to take all such
measures as may be necessary to ensure that animals are not
subjected to unnecessary pain or suffering before, during or
after the performance of experiments on them.
13
14. Goals
The goal of these guidelines is to promote the human care of
animal used in biomedical and behavioural research and
testing.
To avoid/minimize pain and suffering inflicted on
experimental animals
Inspection of animal house facilities
It provides guidelines for -
Proper care, housing, breeding, maintenance, handling and
use of experimental animals.
Source of experimental animals
Acceptable experimental procedures for anaesthesia and
euthanasia.
14
15. Functions of CPCSEA
Registration of establishments conducting animal
experimentation or breeding of animals for this purpose.
Selection and assignment of nominees for the Institutional
Animal Ethics Committees (IAEC) of the registered
establishments.
Approval of Animal House Facilities on the basis of reports
of inspections conducted by CPCSEA.
Permission for conducting experiments involving use of
animals.
Recommendation for import of animals for use in
experiments.
Action against establishments in case of established
violation of any legal norm/stipulation.
15
16. Cont...
Conduct of Training Programmes for the Nominees of
CPCSEA.
Conduct/Support of Conference/Workshop on Animal
Ethics.
Requirement of form in CPCSEA supervision
16
Application for registration of breeder/ establishment/
educational institution
(Form A).
Application for permission for animal experiments (Form B).
Record of animals bred/acquired and record of animals
acquired and experiments performed
(Form C
and D).
Record of animals sold to the establishment by the traders (Form-E).
17. Maintenance of laboratory animals
as per CPCSEA guidelines
To assure quality maintenance and safety of animals used
in laboratory studies while conducting biomedical and
behavioural research and testing of products.
Goal: To provide the specification that will enhance animal
wellbeing, quality in the advancement of biological
knowledge that is relevant to humans and animals.
1. Quarantine
2. Personal hygiene
3. Environment
4. Physical facility
5. Animal husbandry
6. Animal disposal
7. Documentation
17
18. Cont...
1. Veterinary Care:
A mechanism of direct and frequent communication should
be adopted so that timely and accurate information on
problems in animal health, behaviour, and well being is
conveyed to the attending veterinarian.
Observed regularly for sign of illness, injury, or abnormal
behaviour.
Contagious disease - isolated from healthy animal.
18
19. Cont...
2. Animal Procurement:
All must be acquired lawfully as per the CPCSEA
guidelines.
Rodents can be imported from abroad after necessary
licence from Director General of Foreign trade (DGFT) is
obtained for import.
A health surveillance program for screening incoming
animals should be carried out before purchase to assess
animal quality.
Each consignment of animals should be inspected for
compliance with procurement specifications
Animals should be quarantined and stabilized according
to procedures
19
20. Cont...
3. Quarantine, Stabilization And Separation:
Quarantine is the separation of newly received animals from
those already in the facility
Duration at quarantine in small lab animals is from one
week to one month and large animals allowed up to 6
weeks.
Physical separation of animals by species is recommended
to prevent interspecies disease transmission
20
21. Cont...
4. Surveillance, Diagnosis, Treatment and Control of
Disease:
All animals should be observed for signs of illness, injury,
or abnormal behaviour by animal house staff.
Post-mortem examination and signs of illness, distress, or
other deviations from normal health condition should be
reported promptly.
Laboratory services should include necropsy,
histopathology, microbiology, clinical pathology, serology,
and parasitological as well as other routine or specialized
laboratory procedures
21
22. Cont...
5. Animal Care and Technical Personnel:
Animal care programs require technical and husbandry
support.
People trained in laboratory animal science or provide for
both formal and on-the- job training
6. Personal Hygiene:
Clothing suitable for use in the animal facility
Personnel should not be permitted to eat, drink, smoke or
apply cosmetics and perfumes in animal rooms.
It is acceptable to use disposable gloves, masks, head
covers, coats, coveralls and shoe covers
22
23. Cont...
7. Animal Experimentation Involving Hazardous Agents:
Institutions should have policies governing experimentation
with hazardous agents.
Since the use of animals in such studies requires special
considerations, the procedures and the facilities to be used
must be reviewed by both the Institutional Bio-safety
committee and Institutional Animal Ethics Committee
(IAEC).
8. Multiple Surgical Procedures On Single Animal:
Multiple surgical procedures on a single animal for any
testing or experiment are not to be practiced.
Individual animals should not be used in more than one
experiment.
23
24. Cont...
9. Durations of Experiments:
No animal should be used for experimentation for more than
3 years unless adequate justification is provided.
10. Physical Restraint:
Prolonged restraint of any animal, including the chairing of
non-human primates, should be avoided unless essential to
the research objectives.
Animals should be handled by competent individuals
trained in methods that cause minimal distress and injury
Restraint devices cannot be used simply as a convenience in
handling or managing animals
Provision should be made for observation of the animal at
appropriate intervals.
24
25. Cont...
11. Location Of Animal Facilities To Laboratories:
Physical separation of animal facilities from personnel areas
such as offices, break room, training and education room.
It is important that they shall be housed in an isolated
building located as far away from human habitations as
possible and not exposed to dust, smoke, noise, wild
rodents, insects and birds.
12. Functional Areas:
Animal housing facilities that are small, maintain few
animals or maintain animals under special conditions.
Equipment, if hazardous biological, physical, or chemical
agents are to be used Receiving and storage areas for food,
bedding
25
26. Cont...
13. Physical Facilities
The design and size of an animal facility depend on the
scope of institutional research activities, animals to be
housed, physical relationship to the rest of the institution,
and geographic location.
Housing facility should be:
i. Designed and operated to facilitate control of
environmental factors
ii. Kept clean and tidy and operated to achieve maximum
possible hygiene.
iii. Pest control programme to monitor and control vermin.
iv. Adequate and appropriate storage areas for food, bedding
and equipment.
26
27. References
1. National Research Council (US) Committee to Update
Science, Medicine, and Animals. Science, Medicine, and
Animals. Washington (DC): National Academies Press
(US); 2004. Safety Testing. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK24645
2. Guidelines for Research Ethics in Science and
Technology. Jahrbuch für Wissenschaft und Ethik.
2017;22(1): 439-456.
3. Nizamuddin Q, Rahman SA. Animal Welfare in Asia:
Specific Flaws and Strengths, Future Trends and Objectives
4. CPCSEA guidelines for laboratory animal facility, Indian
Journal of Pharmacology 2003;35:257-
274.https://www.cvsccauaizawl.edu.in/sites/default/files/file
s/iaec/cpcsea_laboratory.pdf
27